FIELD: pharmaceuticals.
SUBSTANCE: present invention relates to creation of therapeutic agents. Disclosed is a method for preparing a conjugate of a drug with an antibody (ADC), comprising the steps of producing a capped antibody in a cell culture, where the capping fragments are selected from 5-thio-2-nitrobenzoic acid (TNB), 2-mercaptopyridine and dithiodipyridine (DTDP); subjecting the capped antibody to the action of a reducing agent which is three (3-sulphophenyl) phosphine (TSPP); and without introduction of oxidising agent conjugation of reduced sulfur bonds on antibody with payload by binding fragment, wherein said payload is auristatin, splice statin or calicheamicin.
EFFECT: conjugates obtained in this way have higher efficacy and can be used in therapy.
6 cl, 16 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROCESS OF LARGE-SCALE PRODUCTION OF CAPPED AND UNCAPPED ANTIBODY CYSTEINES AND THEIR APPLICATION FOR THERAPEUTIC PROTEIN CONJUGATION | 2018 |
|
RU2759602C2 |
| METHOD FOR DOUBLE CONJUGATION FOR OBTAINING ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2771310C2 |
| RADIOACTIVE ZIRCONIUM- LABELLED ENGINEERED CYSTEINE ANTIBODIES CONJUGATES | 2010 |
|
RU2562862C2 |
| COVALENT BONDED POLYPEPTIDE TOXIN AND ANTIBODY CONJUGATES | 2014 |
|
RU2682754C2 |
| ANTIBODIES WITH CYSTEINE SUBSTITUITIONS AND THEIR CONJUGATES PRODUCED BY GENE ENGINEERING | 2011 |
|
RU2626537C2 |
| ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATION | 2007 |
|
RU2436796C9 |
| ANTIBODIES AGAINST TENB2 CONSTRUCTED WITH CYSTEINE, AND CONJUGATES, ANTIBODY-DRUG | 2008 |
|
RU2505544C2 |
| MULTISPECIFIC ANTIBODIES, THEREOF ANALOGUES, COMPOSITIONS AND METHODS | 2010 |
|
RU2580038C2 |
| ANTIBODIES WITH CYSTEINE SUBSTITUTIONS OBTAINED BY GENETIC ENGINEERING AND THEIR CONJUGATES | 2011 |
|
RU2755066C2 |
| ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATIONS | 2007 |
|
RU2639543C9 |
